Testing KIVU-305 for Advanced Solid Tumors
Part of Cancer, Digestive system clinical trials.
This study tests a new cancer drug called KIVU-305 in people with advanced or metastatic solid tumors (cancer that has spread) that haven't responded to standard treatments. The drug is designed to target cancer cells while minimizing harm to healthy cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with advanced or metastatic solid tumor cancer that didn't respond to standard treatment or has no standard treatment available
- Good organ function in bone marrow, kidneys, and liver
- Cancer can be measured on scans using standard imaging criteria (RECIST v1.1)
- Good overall health status (ECOG performance score of 0 or 1, meaning able to do light activities)
- Life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
This trial tests a new drug called VIB305 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if VIB305 is safe and how it affects the tumors.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.